Strong Buy Rating for Supernus Pharmaceuticals Amidst Robust Revenue Growth and Qelbree's Market Success
Buy Rating Affirmed for Revolve Group Amid Strong Financial Performance and Growth Prospects
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Raises Target Price to $30
TD Cowen Maintains Dynavax Technologies(DVAX.US) With Buy Rating, Maintains Target Price $25
Goldman Sachs Maintains Halozyme Therapeutics(HALO.US) With Hold Rating
TD Cowen Keeps Their Hold Rating on Myriad Genetics (MYGN)
Halozyme Therapeutics Inc.: A Hold Rating Amidst Steady Financials and Anticipated Developments
Scotiabank Maintains Sector Outperform on Sunnova Energy Intl, Raises Price Target to $14
Harmony Biosciences Holdings Sell Rating Affirmed Amid Slowing Patient Growth and Unchanged Revenue Guidance
Analysts Have Conflicting Sentiments on These Technology Companies: BlackLine (BL) and Venture (OtherVEMLF)
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating
William Blair Maintains BlackLine(BL.US) With Hold Rating
Goldman Sachs Maintains Green Plains Inc(GPRE.US) With Buy Rating, Cuts Target Price to $30
TD Cowen Maintains Macrogenics(MGNX.US) With Hold Rating
Capital One Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $48
Goldman Sachs Maintains Harmony Biosciences(HRMY.US) With Sell Rating, Announces Target Price $28
Goldman Sachs Maintains Mueller Water Products(MWA.US) With Hold Rating
Maintaining Buy Rating on Green Plains Inc. Amidst Strategic Transformations and Revised EBITDA Estimates
Hold Rating on MacroGenics Amid Trial Uncertainties and Safety Concerns